Search Results - "Molinas, F.C."

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
  2. 2

    Anagrelide platelet‐lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms by Espasandin, Y. R., Glembotsky, A. C., Grodzielski, M., Lev, P. R., Goette, N. P., Molinas, F. C., Marta, R. F., Heller, P. G.

    Published in Journal of thrombosis and haemostasis (01-04-2015)
    “…Summary Background and Objectives Anagrelide represents a treatment option for essential thrombocythemia patients. It lowers platelet counts through inhibition…”
    Get full text
    Journal Article
  3. 3

    International collaboration as a tool for diagnosis of patients with inherited thrombocytopenia in the setting of a developing country by GLEMBOTSKY, A. C., MARTA, R. F., PECCI, A., DE ROCCO, D., GNAN, C., ESPASANDIN, Y. R., GOETTE, N. P., NEGRO, F., NORIS, P., SAVOIA, A., BALDUINI, C. L., MOLINAS, F. C., HELLER, P. G.

    Published in Journal of thrombosis and haemostasis (01-08-2012)
    “…Background:  Inherited thrombocytopenias (ITs) are heterogeneous genetic disorders that frequently represent a diagnostic challenge. The requirement of highly…”
    Get full text
    Journal Article
  4. 4

    Monocyte IL-2Rα expression is associated with thrombosis and the JAK2V617F mutation in myeloproliferative neoplasms by Goette, N.P., Lev, P.R., Heller, P.G., Kornblihtt, L.I., Korin, L., Molinas, F.C., Marta, R.F.

    Published in Cytokine (Philadelphia, Pa.) (01-07-2010)
    “…The development of bone marrow fibrosis and thrombosis are main causes of morbidity in essential thrombocythemia (ET). Monocyte activation has been associated…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Variation of PDGF, TGFβ, and bFGF levels in essential thrombocythemia patients treated with anagrelide by Lev, P.R., Marta, R.F., Vassallu, P., Molinas, F.C.

    Published in American journal of hematology (01-06-2002)
    “…We studied 15 patients with essential thrombocythemia (ET) before treatment and after normalization of platelet count by anagrelide. Significantly increased…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Relationship between hematopoietic growth factors levels and hematological parameters in Argentine hemorrhagic fever by Marta, R.F., Enria, D., Molinas, F.C.

    Published in American journal of hematology (01-05-2000)
    “…Argentine hemorrhagic fever (AHF) is a viral disease caused by Junin virus and characterized by hematologic and neurological involvement. The main hematologic…”
    Get full text
    Journal Article
  9. 9

    Systemic disorders in Argentine haemorrhagic fever by Marta, R.F., Montero, V.S., Molinas, F.C.

    Published in Bulletin de l'Institut Pasteur (1998)
    “…Patients with Argentine haemorrhagic fever have mainly central nervous system involvement and haemorrhagic manifestations, with leucopenia and…”
    Get full text
    Journal Article
  10. 10